Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with Bevacizumab and XELOX for Rectal Cancer
NCT06808412Phase 2Recruiting
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in rectal cancer. Started Jul 2024; status: recruiting.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06808412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06808412.